Abstract
The prognosis of locally advanced colon cancer (LACC) with surgical resection followed only by adjuvant chemotherapyis poor. Preoperative chemotherapy for LACC patients with risk factorssuch as cT4bN+ or cT3-4aN2-3has attracted attention. Here, the authorsdescribe the rationale and design of JCOG2006, a randomized phase II study comparing preoperative chemotherapy with mFOLFOX6 versus FOLFOXIRI for LACC. Their efficacy and safety areevaluatedand a determination ofwhich is the more promising treatment will beconducted in a subsequent phase III trial. A total of 86patients will be accrued from 44 institutions over 2years. The primary end point is the proportion of patientswith a Tumor Regression Score of 0-2, and secondary end points include overall survival, response rateand adverse events. Clinical Trial Registration: jRCTs031210365 (https://jrct.niph.go.jp/).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
